LMAT · Lemaitre Vascular Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | $47.41M | $55.85M | $53.48M | - |
| Cost of Revenue | $18.16M | - | $15.09M | $19.26M | $18.45M | - | $17.64M | $17.38M | $16.81M | - |
| Gross Profit | $48.40M | - | $45.95M | $44.97M | $41.42M | - | $37.18M | $38.47M | $36.66M | - |
| R&D | $4.06M | - | $2.97M | $3.54M | $4.09M | - | $3.66M | $4.28M | $4.09M | - |
| SG&A | $12.05M | - | $10.75M | $10.40M | $10.49M | - | $8.93M | $8.82M | $9.01M | - |
| Total Operating Expenses | $30.62M | - | $25.64M | $28.83M | $28.79M | - | $24.03M | $24.09M | $24.79M | - |
| D&A | $2.62M | - | - | - | $2.55M | - | - | - | $2.38M | - |
| Operating Income | $17.77M | - | $20.31M | $16.14M | $12.63M | - | $13.15M | $14.38M | $11.87M | - |
| Interest Expense | $1.30M | - | $0 | $0 | $0 | - | - | - | - | - |
| Income Tax | $3.99M | - | $5.21M | $4.29M | $3.23M | - | $3.41M | $3.68M | $2.91M | - |
| Net Income | $15.68M | - | $17.36M | $13.78M | $11.01M | - | $11.14M | $11.83M | $9.89M | - |
| EPS - Basic | $0.69 | - | $0.77 | $0.61 | $0.49 | - | $0.50 | $0.53 | $0.44 | - |
| EPS - Diluted | $0.68 | - | $0.75 | $0.60 | $0.48 | - | $0.49 | $0.52 | $0.44 | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $26.85M | $28.24M | $25.49M | $27.18M | $25.34M | $25.61M | $21.00M | $22.27M | $26.59M | $24.27M |
| Accounts Receivable | $35.77M | $33.61M | $32.42M | $36.54M | $35.11M | $30.06M | $32.27M | $30.82M | $30.24M | $25.06M |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $4.18M | $3.65M | $3.46M | $4.91M | $2.18M | $1.76M | $1.65M | $2.00M | $3.09M | $3.73M |
| Current Assets | $477.82M | $468.23M | $452.02M | $430.13M | $408.11M | $402.19M | $227.12M | $212.81M | $202.96M | $194.60M |
| Total Assets | $629.53M | $615.69M | $598.07M | $577.59M | $556.01M | $551.82M | $377.02M | $363.08M | $353.96M | $346.78M |
| Current Liabilities | $33.37M | $36.32M | $33.29M | $30.82M | $24.75M | $30.61M | $29.34M | $25.45M | $26.81M | $29.88M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $222.90M | $222.17M | $219.15M | $214.91M | $208.43M | $214.53M | $45.95M | $43.55M | $45.45M | $48.88M |
| Stockholders' Equity | $406.62M | $393.52M | $378.92M | $362.69M | $347.57M | $337.29M | $331.07M | $319.53M | $308.50M | $297.90M |
| Retained Earnings | $194.68M | $184.72M | $173.67M | $160.84M | $151.58M | $145.09M | $137.51M | $129.96M | $121.73M | $115.43M |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $15.09M | - | - | - | $9.04M | - | - | - | $5.07M | - |
| Investing Cash Flow | ($13.12M) | - | - | - | ($4.32M) | - | - | - | ($2.36M) | - |
| Financing Cash Flow | ($3.22M) | - | - | - | ($5.24M) | - | - | - | $39.0K | - |
| CapEx | $2.78M | - | - | - | $1.38M | - | - | - | $1.37M | - |
| Free Cash Flow | $12.31M | - | - | - | $7.66M | - | - | - | $3.70M | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | 78.4% | 68.9% | 68.6% | - |
| Operating margin | - | - | - | - | - | - | 27.7% | 25.7% | 22.2% | - |
| EBITDA margin | - | - | - | - | - | - | - | - | 26.7% | - |
| Net margin | - | - | - | - | - | - | 23.5% | 21.2% | 18.5% | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | 6.9% | - |
| FCF / Net income | 0.79 | - | - | - | 0.70 | - | - | - | 0.37 | - |
| R&D / Revenue | - | - | - | - | - | - | 7.7% | 7.7% | 7.7% | - |
| SG&A / Revenue | - | - | - | - | - | - | 18.8% | 15.8% | 16.9% | - |
| Effective tax rate | 20.3% | - | 23.1% | 23.7% | 22.7% | - | 23.4% | 23.7% | 22.7% | - |
| Return on assets | 2.5% | - | 2.9% | 2.4% | 2.0% | - | 3.0% | 3.3% | 2.8% | - |
| Return on equity | 3.9% | - | 4.6% | 3.8% | 3.2% | - | 3.4% | 3.7% | 3.2% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 14.32 | 12.89 | 13.58 | 13.96 | 16.49 | 13.14 | 7.74 | 8.36 | 7.57 | 6.51 |
| Quick ratio | 14.32 | 12.89 | 13.58 | 13.96 | 16.49 | 13.14 | 7.74 | 8.36 | 7.57 | 6.51 |
| Cash ratio | 0.80 | 0.78 | 0.77 | 0.88 | 1.02 | 0.84 | 0.72 | 0.88 | 0.99 | 0.81 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | 13.7x | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.55 | 1.56 | 1.58 | 1.59 | 1.60 | 1.64 | 1.14 | 1.14 | 1.15 | 1.16 |
| Liabilities / Assets | 0.35 | 0.36 | 0.37 | 0.37 | 0.37 | 0.39 | 0.12 | 0.12 | 0.13 | 0.14 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | 0.13 | 0.15 | 0.15 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | 248d | 201d | 206d | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | 84d | - | 84d | 93d | 43d | - | 34d | 42d | 67d | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | 160.5x | - | 116.7x | 138.4x | 174.8x | - | 189.6x | 158.2x | 150.8x | - |
| P / B | 6.2x | - | 5.6x | 5.2x | 5.5x | - | 6.4x | 5.9x | 4.9x | - |
| P / S | - | - | - | - | - | - | 44.7x | 33.5x | 28.0x | - |
| EV / EBITDA | 121.9x | - | - | - | 124.9x | - | - | - | 103.2x | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | 11.4% | 13.6% | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | 7.3% | 11.2% | 14.2% | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | 10.3% | 13.6% | 13.4% | - |
| Gross profit growth (YoY) | 16.8% | - | 23.6% | 16.9% | 13.0% | - | 20.6% | 19.9% | 18.7% | - |
| Operating income growth (YoY) | 40.8% | - | 54.5% | 12.3% | 6.3% | - | 43.2% | 52.1% | 50.8% | - |
| Net income growth (YoY) | 42.4% | - | 55.8% | 16.5% | 11.4% | - | 48.5% | 46.0% | 63.7% | - |
| EPS growth (YoY) | 41.7% | - | 53.1% | 15.4% | 9.1% | - | 48.5% | 44.4% | 63.0% | - |
| EPS CAGR (3y) | 36.1% | - | 44.2% | 55.4% | 21.1% | - | 17.8% | 9.1% | 16.3% | - |
| EPS CAGR (5y) | 19.4% | - | 15.2% | 28.7% | 24.6% | - | 14.4% | 17.7% | 20.9% | - |
| FCF growth (YoY) | 60.8% | - | - | - | 106.9% | - | - | - | 2383.9% | - |
| FCF CAGR (5y) | 19.7% | - | - | - | 88.0% | - | - | - | 4.6% | - |
| Book value growth (YoY) | 17.0% | 16.7% | 14.5% | 13.5% | 12.7% | 13.2% | 14.7% | 12.6% | 12.5% | 11.1% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Geographic
$249.60M totalAmericas$159.66M · 64.0%
EMEA$73.12M · 29.3%
Asia Pacific$16.82M · 6.7%
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing LEMAITRE VASCULAR INC against the 5 most active filers in the same SIC group.
Dividends
$0.90/share trailing 12 months · +25.0% YoY
| Ex-date | Per share |
|---|---|
| May 21, 2026 | $0.2500 |
| Mar 12, 2026 | $0.2500 |
| Nov 20, 2025 | $0.2000 |
| Aug 21, 2025 | $0.2000 |
| May 15, 2025 | $0.2000 |
| Mar 13, 2025 | $0.2000 |
| Nov 21, 2024 | $0.1600 |
| Aug 15, 2024 | $0.1600 |
| May 15, 2024 | $0.1600 |
| Mar 13, 2024 | $0.1600 |
| Nov 15, 2023 | $0.1400 |
| Aug 16, 2023 | $0.1400 |
| May 16, 2023 | $0.1400 |
| Mar 8, 2023 | $0.1400 |
| Nov 16, 2022 | $0.1250 |
| Aug 24, 2022 | $0.1250 |
| May 16, 2022 | $0.1250 |
| Mar 7, 2022 | $0.1250 |
| Nov 18, 2021 | $0.1100 |
| Aug 25, 2021 | $0.1100 |
| May 18, 2021 | $0.1100 |
| Mar 8, 2021 | $0.1100 |
| Nov 18, 2020 | $0.0950 |
| Aug 26, 2020 | $0.0950 |